539 related articles for article (PubMed ID: 25218176)
1. Time course of cytokine upregulation in the lacrimal gland and presence of autoantibodies in a predisposed mouse model of Sjögren's Syndrome: the influence of sex hormones and genetic background.
Czerwinski S; Mostafa S; Rowan VS; Azzarolo AM
Exp Eye Res; 2014 Nov; 128():15-22. PubMed ID: 25218176
[TBL] [Abstract][Full Text] [Related]
2. Influence of sex hormones and genetic predisposition in Sjögren's syndrome: a new clue to the immunopathogenesis of dry eye disease.
Mostafa S; Seamon V; Azzarolo AM
Exp Eye Res; 2012 Mar; 96(1):88-97. PubMed ID: 22227485
[TBL] [Abstract][Full Text] [Related]
3. Sjögren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease.
Gao J; Killedar S; Cornelius JG; Nguyen C; Cha S; Peck AB
J Autoimmun; 2006 Mar; 26(2):90-103. PubMed ID: 16413168
[TBL] [Abstract][Full Text] [Related]
4. Total glucosides of paeony (TGP) alleviates Sjogren's syndrome through inhibiting inflammatory responses in mice.
Li B; Liu G; Liu R; He S; Li X; Huang L; Wang Z; Li Y; Chen Y; Yin H; Fang W
Phytomedicine; 2020 Jun; 71():153203. PubMed ID: 32402913
[TBL] [Abstract][Full Text] [Related]
5. IL-4-STAT6 signal transduction-dependent induction of the clinical phase of Sjögren's syndrome-like disease of the nonobese diabetic mouse.
Nguyen CQ; Gao JH; Kim H; Saban DR; Cornelius JG; Peck AB
J Immunol; 2007 Jul; 179(1):382-90. PubMed ID: 17579059
[TBL] [Abstract][Full Text] [Related]
6. Systemic manifestations of primary Sjögren's syndrome in the NOD.B10Sn-H2
Kiripolsky J; Shen L; Liang Y; Li A; Suresh L; Lian Y; Li QZ; Gaile DP; Kramer JM
Clin Immunol; 2017 Oct; 183():225-232. PubMed ID: 28526333
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of lysophosphatidic acid receptor ameliorates Sjögren's syndrome in NOD mice.
Park E; Kim D; Lee SM; Jun HS
Oncotarget; 2017 Apr; 8(16):27240-27251. PubMed ID: 28460477
[TBL] [Abstract][Full Text] [Related]
8. Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sjögren's syndrome and in mice.
Yin H; Cabrera-Perez J; Lai Z; Michael D; Weller M; Swaim WD; Liu X; Catalán MA; Rocha EM; Ismail N; Afione S; Rana NA; Di Pasquale G; Alevizos I; Ambudkar I; Illei GG; Chiorini JA
Arthritis Rheum; 2013 Dec; 65(12):3228-38. PubMed ID: 23982860
[TBL] [Abstract][Full Text] [Related]
9. Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome.
Fava RA; Kennedy SM; Wood SG; Bolstad AI; Bienkowska J; Papandile A; Kelly JA; Mavragani CP; Gatumu M; Skarstein K; Browning JL
Arthritis Res Ther; 2011; 13(6):R182. PubMed ID: 22044682
[TBL] [Abstract][Full Text] [Related]
10. Immunization with 60 kD Ro peptide produces different stages of preclinical autoimmunity in a Sjögren's syndrome model among multiple strains of inbred mice.
Kurien BT; Dsouza A; Igoe A; Lee YJ; Maier-Moore JS; Gordon T; Jackson M; Scofield RH
Clin Exp Immunol; 2013 Jul; 173(1):67-75. PubMed ID: 23607771
[TBL] [Abstract][Full Text] [Related]
11. Matriptase deletion initiates a Sjögren's syndrome-like disease in mice.
Yin H; Kosa P; Liu X; Swaim WD; Lai Z; Cabrera-Perez J; Di Pasquale G; Ambudkar IS; Bugge TH; Chiorini JA
PLoS One; 2014; 9(2):e82852. PubMed ID: 24551030
[TBL] [Abstract][Full Text] [Related]
12. Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjögren's syndrome.
Yin H; Nguyen CQ; Samuni Y; Uede T; Peck AB; Chiorini JA
Arthritis Res Ther; 2012 Feb; 14(1):R40. PubMed ID: 22369699
[TBL] [Abstract][Full Text] [Related]
13. Anti-Ro/SSA and anti-La/SSB autoantibodies in the tear fluid of patients with Sjögren's syndrome.
Toker E; Yavuz S; Direskeneli H
Br J Ophthalmol; 2004 Mar; 88(3):384-7. PubMed ID: 14977774
[TBL] [Abstract][Full Text] [Related]
14. Investigation of novel autoantibodies in Sjogren's syndrome utilizing Sera from the Sjogren's international collaborative clinical alliance cohort.
Suresh L; Malyavantham K; Shen L; Ambrus JL
BMC Ophthalmol; 2015 Apr; 15():38. PubMed ID: 25881294
[TBL] [Abstract][Full Text] [Related]
15. Early Covert Appearance of Marginal Zone B Cells in Salivary Glands of Sjögren's Syndrome-Susceptible Mice: Initiators of Subsequent Overt Clinical Disease.
Peck AB; Nguyen CQ; Ambrus J
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671965
[TBL] [Abstract][Full Text] [Related]
16. Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NOD mouse model of Sjögren's syndrome.
Yanagi K; Ishimaru N; Haneji N; Saegusa K; Saito I; Hayashi Y
Eur J Immunol; 1998 Oct; 28(10):3336-45. PubMed ID: 9808203
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal Stem Cells Extract (MSCsE)-Based Therapy Alleviates Xerostomia and Keratoconjunctivitis Sicca in Sjogren's Syndrome-Like Disease.
Abughanam G; Elkashty OA; Liu Y; Bakkar MO; Tran SD
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557796
[TBL] [Abstract][Full Text] [Related]
18. Innate Immune Signaling Induces IL-7 Production, Early Inflammatory Responses, and Sjögren's-Like Dacryoadenitis in C57BL/6 Mice.
Zhou J; Jin JO; Du J; Yu Q
Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):7831-8. PubMed ID: 26658504
[TBL] [Abstract][Full Text] [Related]
19. Myd88 is required for disease development in a primary Sjögren's syndrome mouse model.
Kiripolsky J; McCabe LG; Gaile DP; Kramer JM
J Leukoc Biol; 2017 Dec; 102(6):1411-1420. PubMed ID: 28951424
[TBL] [Abstract][Full Text] [Related]
20. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome.
Fox RI; Kang HI; Ando D; Abrams J; Pisa E
J Immunol; 1994 Jun; 152(11):5532-9. PubMed ID: 8189070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
